Using SIV in rhesus monkeys for AIDS vaccine development.

Important note: Information in this article was accurate in 1994. The state of the art may have changed since the publication date.

Using SIV in rhesus monkeys for AIDS vaccine development.

Symp Nonhum Primate Models AIDS. 1993 Sep 19-22;11:abstract no. 21. Unique Identifier : AIDSLINE PRIM11/94191614
Desrosiers RC; New England Regional Primate Research Center, Harvard Medical; School, Southborough, MA 01772.

Abstract: Historically, vaccines have been our most potent weapon against viral diseases of medical importance. Development of an effective vaccine against HIV holds the greatest promise for preventing what will otherwise be a public health disaster of catastrophic proportions. Unfortunately, there are good reasons for believing that development of an effective vaccine for HIV-1 in humans is going to be a very difficult task. The predicted difficulty in achieving protection against HIV and SIV has more or less been borne out by vaccine trials in animal models. Disappointing vaccine results have been obtained in my own laboratory in the SIV system using inactivated whole virus, env protein, monovalent vaccinia recombinant expressing env, trivalent vaccinia recombinant expressing gag, pol and env that can assemble into pseudovirion particles, and trivalent vaccinia recombinant priming followed by particle boosting. These disappointing trends suggest that more radical approaches may be needed. Promising results have recently been obtained with single and multiple deletion mutants of SIV in the rhesus monkey model. Safety and potency issues relevant to development of a live-attenuated multiply-deleted HIV-1 vaccine for AIDS will be discussed.

Keywords: Acquired Immunodeficiency Syndrome/IMMUNOLOGY/*PREVENTION & CONTROL Animal *AIDS Vaccines Disease Models, Animal Gene Products, env/IMMUNOLOGY Gene Products, gag/IMMUNOLOGY Gene Products, pol/IMMUNOLOGY Human HIV-1/*IMMUNOLOGY Macaca mulatta Sequence Deletion Simian Acquired Immunodeficiency Syndrome/*IMMUNOLOGY/PREVENTION & CONTROL SIV/*IMMUNOLOGY Vaccines, Inactivated/THERAPEUTIC USE Vaccines, Synthetic/THERAPEUTIC USE Viral Vaccines/*THERAPEUTIC USE ABSTRACT
940730
M9470904

AEGiS is a 501(c)3, not-for-profit, tax-exempt, educational corporation. AEGiS is made possible through unrestricted funding from Boehringer Ingelheim, Bridgestone/Firestone Charitable Trust, Bristol-Myers Squibb Company, Elton John AIDS Foundation, Gill Foundation, the National Library of Medicine, Quest Diagnostics, Roche and Trimeris, and donations from users like you. Always watch for outdated information. This article first appeared in 1994. This material is designed to support, not replace, the relationship that exists between you and your doctor.

AEGiS presents published material, reprinted with permission and neither endorses nor opposes any material. All information contained on this website, including information relating to health conditions, products, and treatments, is for informational purposes only. It is often presented in summary or aggregate form. It is not meant to be a substitute for the advice provided by your own physician or other medical professionals. Always discuss treatment options with a doctor who specializes in treating HIV.

Copyright ©1980, 1994. AEGiS. All materials appearing on AEGiS are protected by copyright as a collective work or compilation under U.S. copyright and other laws and are the property of AEGiS, or the party credited as the provider of the content. .